---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-26-013429"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2026-06-25T12:21:30+00:00"
generated_at: "2026-06-25T12:25:24.089564+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Merck KGaA to acquire Bio-Techne for $73/share in $11.3B deal

## Summary
- Purchase price $73/share in cash; enterprise value $11.3B (EUR 9.9B); 36% premium to 1-month VWAP.
- Expected to close by late 2026 / early 2027, subject to shareholder and regulatory approvals.
- Annual cost synergies of ~EUR 140M expected fully realized by year 3 post-close.
- Bio-Techne FY2025 net sales >$1.2B; ~3,000 employees; to operate as part of Merck KGaA Life Science.
- Transaction approved by Bio-Techne Board and Merck corporate bodies; debt-funded with investment-grade credit maintained.

## SEC filing metadata
- accession: 0001999371-26-013429
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2026-06-25T12:21:30+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000199937126013429/0001999371-26-013429-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000199937126013429/tech-8k_062526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-26-013429
- JSON: https://secwatch.observer/filing/0001999371-26-013429.json
- Plain text: https://secwatch.observer/filing/0001999371-26-013429.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.